Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study

AIMS: To compare the once‐weekly glucagon‐like peptide‐1 (GLP‐1) receptor dulaglutide with the dipeptidyl peptidase‐4 (DPP‐4) inhibitor sitagliptin after 104 weeks of treatment. METHODS: This AWARD‐5 study was a multicentre, double‐blind trial that randomized participants to dulaglutide (1.5 or 0.75...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinstock, R. S., Guerci, B., Umpierrez, G., Nauck, M. A., Skrivanek, Z., Milicevic, Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008205/
https://www.ncbi.nlm.nih.gov/pubmed/25912221
http://dx.doi.org/10.1111/dom.12479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008205/
https://www.ncbi.nlm.nih.gov/pubmed/25912221
http://dx.doi.org/10.1111/dom.12479

Ejemplares similares